Esperion Therapeutics, Inc. (ESPR) insider trading.
In Q3 2026, insiders at Esperion Therapeutics, Inc. reported 9 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 0 sales.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 0
- Net shares, P minus S
- 0
- Insiders
- 9
- Last filed
- 2026-07-13
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Koenig Sheldon L. | Director, Officer · President and CEO | 1 | 0 | 0 |
| Halladay Benjamin | Officer · Chief Financial Officer | 1 | 0 | 0 |
| Looker Benjamin | Officer · Chief Legal Officer | 1 | 0 | 0 |
| Harlow John B. Jr. | Officer · Chief Commercial Officer | 1 | 0 | 0 |
| Thompson John Craig | Director | 1 | 0 | 0 |
| Fischer Seth H. Z. | Director | 1 | 0 | 0 |
| Shepard Jay | Director | 1 | 0 | 0 |
| Carroll J Martin | Director | 1 | 0 | 0 |
| Hoffman Robert E. | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | Koenig Sheldon L. | D (D) | 2,121,094 | — | 0 | Form 4 |
| 2026-07-13 | Halladay Benjamin | D (D) | 705,410 | — | 0 | Form 4 |
| 2026-07-13 | Looker Benjamin | D (D) | 667,524 | — | 0 | Form 4 |
| 2026-07-13 | Harlow John B. Jr. | D (D) | 424,536 | — | 0 | Form 4 |
| 2026-07-13 | Thompson John Craig | D (D) | 79,873 | — | 0 | Form 4 |
| 2026-07-13 | Fischer Seth H. Z. | D (D) | 141,023 | — | 0 | Form 4 |
| 2026-07-13 | Shepard Jay | D (D) | 164,472 | — | 0 | Form 4 |
| 2026-07-13 | Carroll J Martin | D (D) | 177,523 | — | 0 | Form 4 |
| 2026-07-13 | Hoffman Robert E. | D (D) | 85,153 | — | 0 | Form 4 |
Transaction codes in this quarter
Get ESPR insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1434868&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · Esperion Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Esperion Therapeutics, Inc. (ESPR)?
In Q3 2026, insiders at Esperion Therapeutics, Inc. reported 9 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Esperion Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/espr.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.